person · Reporting owner

Wigzell Hans Lennart Rudolf

Disclosed activity across 1 company

Tapewire entity: 41122
SEC CIK: 0001492766

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Sarepta Therapeutics, Inc.SRPT · Entity 4426	Director	June 04, 2026	June 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Sarepta Therapeutics, Inc.

Report date June 04, 2026 · Filed June 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	42,098	Reported balance After 2026-06-04 transaction · row 1 1 source row Row 1 · 2026-06-04 · Grant · Acquired 16,875 · Balance 42,098 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 30, 2017 Filed Dec 5, 2017 01:00 UTC	Sarepta Therapeutics, Inc. SRPT · Entity 4426	SaleCommon Stock	6,667	$55.89	$372,618.63	Disclosure SEC source: 0001209191-17-063683 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.87 to $55.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above. Read SEC document
November 30, 2017 Filed Dec 5, 2017 01:00 UTC	Sarepta Therapeutics, Inc. SRPT · Entity 4426	Exercise / conversionCommon Stock	6,667	$7.38	$49,202.46	Disclosure SEC source: 0001209191-17-063683 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.87 to $55.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above. Read SEC document
March 10, 2017 Filed Mar 15, 2017 01:46 UTC	Sarepta Therapeutics, Inc. SRPT · Entity 4426	GrantNon-Qualified Stock Option (right to buy) · Derivative	12,350	$0.00 Strike: $32.63	$0.00	Disclosure SEC source: 0001209191-17-020687 · doc4.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document
March 10, 2017 Filed Mar 15, 2017 01:46 UTC	Sarepta Therapeutics, Inc. SRPT · Entity 4426	GrantCommon Stock	1,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-020687 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.